Daiichi integrates ingredient plants; BMS picks LabCorp; Analyst disses Hospira;

> CRO PPD has received approval from Brazilian regulators to do bioanalytical work on compounds for clients at a certified facility and also is expanding capabilities at a facility in Wisconsin. Report

> Daiichi Sankyo has combined its Daiichi Sankyo Propharma and Daiichi Sankyo Chemical Pharma Odawara plants to create an integrated system for making intermediates and APIs. Item

> Drugmakers in East Africa will work together in an effort to build the capacity to meet half the region's drug needs. Report

> Bristol-Myers Squibb ($BMY) has made LabCorp its preferred provider for laboratory services. Item

>  Zacks.com is warning investors away from buying shares in Hospira ($HSP) until the company can get out from under a cloud of FDA issues. Report

And Finally... While the number of drug shortages in the U.S. has declined, shortages continue to illicit comments of concern from the entire spectrum of healthcare providers. Comments